SWM
FBIO icon

Spire Wealth Management’s Fortress Biotech FBIO Stock Holding History

Spire Wealth Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-133
Closed -$7K – 2593
2021
Q2 		$7K Buy
+133
New +$8.02K ﹤0.01% 2226

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Shikiar Asset Management New York $347M AUM 23.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CL
CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Spire Wealth Management's FBIO Position: Q3 2021 in Review

Spire Wealth Management sold out of Fortress Biotech (FBIO) in Q3 2021, closing a stake of 133 shares — an estimated $7K sold.

Spire Wealth Management first reported a position in FBIO in Q2 2021 and held it in 1 quarter. The position peaked at $7K in Q2 2021. 79 funds tracked by Wall St. Rank hold FBIO as of Q3 2021.

  • Spire Wealth Management reported no remaining Fortress Biotech position as of Q3 2021 after selling out during the quarter.
  • Spire Wealth Management sold 133 Fortress Biotech shares in Q3 2021, an estimated $7K.
  • Spire Wealth Management first reported a position in Fortress Biotech in Q2 2021 and held it in 1 quarter.
  • Spire Wealth Management's Fortress Biotech position peaked at $7K in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2021.

Based on Spire Wealth Management's 13F filing for Q3 2021, filed 22 Oct 2021.